07:00 , Oct 22, 2015 |  BC Innovations  |  Translation in Brief

Unique ubiquity

A University of Lausanne team has turned to the U.K.'s MRC Technology for help in developing a therapeutic from the team's 2013 finding that monoubiquitination can activate the protease MALT1 in diffuse large B cell...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

MRC Technology, University of Lausanne deal

MRC Technology and the university partnered to develop small molecules inhibitors of mucosa associated lymphoid tissue lymphoma translocation protein 1 ( MALT1) to treat diffuse large B cell lymphoma. The immunomodulatory enzyme is required to...
08:00 , Jan 22, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Epigenetic markers of susceptibility to type 2 diabetes

Bio Markers TECHNOLOGY: Gene profiling An epigenomic analysis of monozygotic twins identified markers of susceptibility to type 2 diabetes. The study examined pairs of adult monozygotic twins of three different types: pairs with type 2 diabetes; pairs...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Company News

AstraZeneca, Center for Drug Design and Discovery (CD3), Flanders Institute for Biotechnology (VIB) deal

AstraZeneca received exclusive, worldwide rights to develop and commercialize small molecule mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1) inhibitors from life science research institute VIB and CD3. The partners hope to develop...
08:00 , Feb 6, 2014 |  BC Innovations  |  Cover Story

Germinating MALT1

AstraZeneca plc has teamed up with the Flanders Institute for Biotechnology and the Centre for Drug Design and Discovery to make the first disclosed industry play for inhibitors of MALT1. The deal announcement caps five...
08:00 , Jan 17, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer B cell lymphoma Mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1) In vitro and mouse studies...
08:00 , Nov 29, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) Mucosa associated lymphoid tissue lymphoma translocation gene 1 (MALT1) In vitro and mouse...
07:00 , Jun 21, 2012 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse model of human mucosa associated lymphoma tissue (MALT) lymphoma A MALT lymphoma model could be used to test...
08:00 , Feb 17, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Cancer Lymphoma MAP kinase kinase kinase 14 (MAP3K14; NIK); baculoviral IAP repeat-containing 3 (BIRC3; cIAP2); mucosa associated lymphoid...
08:00 , Nov 19, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer B cell lymphoma Mucosa...